#kidney

Transplantees can be treated safely and effectively for hep C, so greater education regarding such methods is in order.

Researchers analyzed health data from 2004 and 2014 regarding a cohort of people with HIV who initially had a median age of 41.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Advocate John Tenorio could be the first HIV-positive person to receive a kidney from a living donor with HIV.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.

Nevertheless, researchers advise careful kidney monitoring when pairing the medications.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

That’s compared with HIV-negative men.

It’s the NIH’s first large-scale clinical trial on the subject. Plus: Meet organ transplant advocate Mo Murray [VIDEO].

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.